Can SGLT-2 inhibitors improve cardiovascular outcomes and ensure safety for patients with type 2 diabetes and heart failure in Thailand? A real-world multicentre retrospective cohort study
SGLT2i significantly improved cardiovascular outcomes in patients with T2D and HF in a real-world clinical setting. These findings support the incorporation of SGLT2i in the management of high-risk patients with T2D and HF. Further research is warranted to explore long-term outcomes and barriers to SGLT2i prescription in routine practice.
Authors
- Amarit Tansawet (ORCID: https://orcid.org/0000-0002-2040-7970)
- Panu Looareesuwan (ORCID: https://orcid.org/0000-0001-8179-9149)
- Tanawan Kongmalai (ORCID: https://orcid.org/0000-0002-1192-9267)
- Oraluck Pattanaprateep (ORCID: https://orcid.org/0000-0001-9570-2635)
- Varalak Srinonprasert (ORCID: https://orcid.org/0000-0001-5311-7657)
- Hataikarn Nimitphong (ORCID: https://orcid.org/0000-0003-0151-1622)
- Ammarin Thakkinstian (ORCID: https://orcid.org/0000-0001-9991-386X)
- Anon Khunakorncharatphong (ORCID: https://orcid.org/0000-0001-6380-9200)
- Porntep Amornritvanich (ORCID: https://orcid.org/0009-0004-2970-4594)
- Cholatid Ratanatharathorn (ORCID: https://orcid.org/0000-0002-1439-371X)
- Burin Boonwatcharapai
Institutions
- Siriraj Hospital (TH)
- Mahidol University (TH)
- Navamindradhiraj University (TH)
- Vajira Hospital (TH)
- Ramathibodi Hospital (TH)
Publication Details
- Journal
- BMJ Open
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1136/bmjopen-2024-090226
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.07
Funders
- National Research Council of Thailand